GLSHQ: AI 评分 65/100 — AI 分析 (4月 2026)

Gelesis Holdings, Inc. is a biotherapeutics company focused on developing treatments for obesity and GI-related chronic diseases. The company filed for liquidation under Chapter 7 bankruptcy in October 2023.

Key Facts: AI Score: 65/100 Sector: Healthcare

公司概况

概要：

Gelesis Holdings, Inc. was a commercial-stage biotherapeutics company focused on developing treatments for obesity and gastrointestinal disorders, most notably its weight management aid, PLENITY. The company's innovative approach using biomimicry aimed to address the underlying causes of these chronic conditions before filing for Chapter 7 liquidation.

GLSHQ是做什么的？

Gelesis Holdings, Inc., incorporated in 2006 and headquartered in Boston, Massachusetts, was a biotherapeutics company dedicated to developing novel treatments for obesity and GI-related chronic diseases. The company's core technology revolved around biomimicry, creating therapies that mimic natural biological processes to address the root causes of these conditions. Their flagship product, PLENITY, was an orally administered, non-stimulant, and non-systemic aid for weight management, designed to help individuals feel fuller and eat less. In addition to PLENITY, Gelesis was developing a pipeline of product candidates, including GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and GS300, a pre-clinical product for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). However, on October 30, 2023, Gelesis Holdings, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, effectively ceasing operations and development efforts.

GLSHQ的投资论点是什么？

Gelesis Holdings, Inc. presented an investment case centered on its innovative biomimicry approach to treating obesity and GI-related disorders. The company's lead product, PLENITY, had the potential to capture a significant share of the weight management market. However, the company's negative gross margin of -61.4% and negative free cash flow of $-0.00B indicated significant financial challenges. The high beta of 3627.55 suggested extreme volatility. The Chapter 7 liquidation filing in October 2023 represents a complete loss of investment for shareholders, as the company's assets are being liquidated to pay off creditors.

GLSHQ在哪个行业运营？

Gelesis Holdings, Inc. operated within the biotechnology sector, specifically targeting the obesity and GI-related disease market. This market is characterized by a growing prevalence of obesity and related conditions, driving demand for innovative treatments. However, the biotechnology industry is highly competitive, with numerous companies developing pharmaceutical and medical device solutions. Gelesis's bankruptcy filing highlights the challenges faced by companies in this sector, including the high costs of research and development, regulatory hurdles, and the need for strong commercial execution.

Biotechnology

Healthcare

GLSHQ有哪些增长机遇？

Expansion of PLENITY: Prior to its bankruptcy filing, Gelesis aimed to expand the market reach of PLENITY, its weight management aid. The weight management market is estimated to be worth billions of dollars globally, with a growing demand for non-prescription and non-systemic solutions. Gelesis's strategy involved increasing awareness and accessibility of PLENITY through partnerships with healthcare providers and direct-to-consumer marketing. However, the company's liquidation has halted these expansion efforts.
Development of GS200 for Prediabetes and Type 2 Diabetes: Gelesis was developing GS200 as a potential treatment for weight loss in individuals with prediabetes and type 2 diabetes. This represents a significant market opportunity, as the prevalence of diabetes continues to rise globally. The company's biomimicry approach could have offered a novel mechanism of action compared to existing diabetes medications. However, the development of GS200 has been discontinued due to the bankruptcy filing.
Advancement of GS500 for Functional Constipation: Gelesis was also working on GS500 for the treatment of functional constipation. Functional constipation is a common GI disorder affecting millions of people worldwide. The company's approach aimed to address the underlying causes of constipation by modulating the gut microbiome. However, the development of GS500 has been terminated as a result of the liquidation.
Pre-clinical Development of GS300 for NAFLD/NASH: Gelesis had a pre-clinical program, GS300, targeting non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NAFLD and NASH are growing health concerns, with limited treatment options currently available. The company's biomimicry platform could have offered a potential therapeutic approach. However, the pre-clinical development of GS300 has been halted due to the bankruptcy.
Partnerships and Licensing Agreements: Gelesis could have pursued partnerships and licensing agreements to expand the reach of its products and technologies. Collaborating with larger pharmaceutical companies or medical device manufacturers could have provided access to additional resources and expertise. However, the company's financial difficulties and subsequent bankruptcy filing made it challenging to attract potential partners.

Negative Gross Margin: Gelesis Holdings, Inc. reported a gross margin of -61.4%, indicating that the cost of goods sold exceeded revenue.
Negative Free Cash Flow: The company's free cash flow was $-0.00B, highlighting its inability to generate positive cash flow from operations.
High Beta: With a beta of 3627.55, the stock exhibited extremely high volatility compared to the overall market.
Chapter 7 Liquidation: On October 30, 2023, Gelesis Holdings, Inc. filed for Chapter 7 liquidation, signaling the end of its operations.
No Dividend: The company did not offer a dividend, reflecting its financial instability.

GLSHQ提供哪些产品和服务？

Developed PLENITY, an oral weight management aid.
Utilized biomimicry technology to treat obesity and GI disorders.
Developed GS200 for weight loss in prediabetes and type 2 diabetes (discontinued).
Developed GS500 for functional constipation (discontinued).
Developed GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (pre-clinical, discontinued).
Filed for Chapter 7 liquidation in October 2023.

GLSHQ如何赚钱？

Focused on developing and commercializing prescription and over-the-counter therapies.
Utilized a biomimicry platform to create novel treatments.
Sought partnerships and licensing agreements to expand product reach (prior to bankruptcy).

Individuals seeking weight management solutions.
Patients with prediabetes and type 2 diabetes (potential customers for GS200).
Patients with functional constipation (potential customers for GS500).
Healthcare providers prescribing weight management aids.

Proprietary Biomimicry Technology: Gelesis's biomimicry platform represented a unique approach to treating obesity and GI disorders.
PLENITY's Novel Mechanism of Action: PLENITY's non-stimulant, non-systemic mechanism of action differentiated it from other weight management products.
Pipeline of Product Candidates: Gelesis had a pipeline of product candidates targeting various GI-related conditions (prior to bankruptcy).

GLSHQ的主要风险是什么？

Ongoing: Chapter 7 Liquidation: The ongoing liquidation process poses a significant risk to any remaining assets or potential future value.
Potential: Competition: The weight management and GI therapeutics markets are highly competitive, with numerous companies developing competing products.
Potential: Regulatory Risks: The development and commercialization of pharmaceutical products are subject to strict regulatory requirements.
Ongoing: Financial Instability: The company's bankruptcy filing highlights the risks associated with financial instability and the inability to generate sustainable revenue.

GLSHQ的核心优势是什么？

Innovative biomimicry technology.
PLENITY's novel mechanism of action.
Pipeline of product candidates (prior to bankruptcy).

GLSHQ的劣势是什么？

Negative gross margin.
Negative free cash flow.
Reliance on a single product (PLENITY) for revenue.
Chapter 7 liquidation filing.

GLSHQ有哪些机遇？

Expansion of PLENITY's market reach (prior to bankruptcy).
Development of new product candidates (prior to bankruptcy).
Partnerships and licensing agreements (prior to bankruptcy).

GLSHQ面临哪些威胁？

Competition from other weight management products.
Regulatory hurdles for new product approvals.
Financial instability leading to bankruptcy.
Patent expiration risks.

Key Metrics

MoonshotScore: 65/100

Company Profile

Headquarters: Boston, United States
Employees: 93

AI Insight

AI analysis pending for GLSHQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Gelesis Holdings, Inc. do?

Gelesis Holdings, Inc. was a biotherapeutics company focused on developing and commercializing novel treatments for obesity and GI-related chronic diseases. Their primary product, PLENITY, was an orally administered weight management aid designed to help individuals feel fuller and eat less. The company also had a pipeline of product candidates targeting prediabetes, type 2 diabetes, and functional constipation. However, Gelesis filed for Chapter 7 liquidation in October 2023, ceasing its operations and development efforts.

What do analysts say about GLSHQ stock?

Given that Gelesis Holdings, Inc. has filed for Chapter 7 liquidation, analyst coverage is likely to be minimal or non-existent. The stock is unlikely to be actively traded or followed by institutional investors. Any remaining trading activity would likely be driven by speculation or retail investors. The company's financial difficulties and bankruptcy filing suggest a high degree of risk and uncertainty.

What are the main risks for GLSHQ?

The primary risk for Gelesis Holdings, Inc. is its Chapter 7 liquidation filing. This means that the company's assets are being liquidated to pay off creditors, and there is little to no prospect of recovery for shareholders. Other risks include competition from other weight management products, regulatory hurdles for new product approvals (prior to bankruptcy), and the company's financial instability, which ultimately led to its demise.

How did Gelesis Holdings, Inc. manage intellectual property?

Gelesis relied on patents and proprietary technology to protect its intellectual property, particularly its biomimicry platform and the composition of PLENITY. The strength and breadth of these patents were crucial for maintaining a competitive advantage and attracting potential partners. However, the company's bankruptcy filing may impact the value and enforceability of its intellectual property assets, as they may be subject to sale or assignment during the liquidation process.

What revenue streams did Gelesis Holdings, Inc. have in healthcare?

Gelesis Holdings, Inc.'s primary revenue stream was the sale of PLENITY, its weight management aid. The company generated revenue through direct-to-consumer sales, partnerships with healthcare providers, and distribution agreements with retailers. However, the company's revenue was insufficient to cover its operating expenses, resulting in negative gross margins and free cash flow. The company's bankruptcy filing indicates that its revenue model was not sustainable in the long term.